Physician profile
David J Pohl
NPI 1023437274
$7,119.63
in general payments reported to CMS, 2019-2025
43 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $548 · 2021: $1,641 · 2022: $1,710 · 2023: $1,787 · 2024: $1,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,221.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $989.04 | 2020-2024 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $934.79 | 2020-2024 | Repatha, Otezla, Evenity |
| Abbvie INC. | $812.50 | 2021-2024 | |
| Pfizer INC. | $488.16 | 2021-2024 | |
| Glaxosmithkline, LLC. | $437.90 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $335.48 | 2020-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $302.33 | 2020-2024 | Mounjaro, Jardiance, Trulicity |
| Amarin Pharma, INC. | $282.15 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $237.42 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $220.64 | 2022-2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $205.52 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.05 | 2020-2024 | Jardiance |
| Antares Pharma, INC. | $155.16 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Biohaven Pharmaceuticals, INC. | $143.34 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $134.43 | 2022-2024 | Caplyta |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.